ライフサイエンスコーパス: myelomonocytic leukemia

1 MDS/MPN overlap syndrome (including chronic myelomonocytic leukemia).

2 n found in a subset of patients with chronic myelomonocytic leukemia.

3 ice that closely models juvenile and chronic myelomonocytic leukemia.

4 eloproliferative disorder resembling chronic myelomonocytic leukemia.

5 loid metaplasia, and, less commonly, chronic myelomonocytic leukemia.

6 es, including an increased risk for juvenile myelomonocytic leukemia.

7 viously described BTs with transformation to myelomonocytic leukemia.

8 ws efficacy in a nude mouse model of chronic myelomonocytic leukemia.

9 duct of the t(5;12) translocation in chronic myelomonocytic leukemia.

10 ight loss as initial manifestations of acute myelomonocytic leukemia.

11 d growth factor beta receptor causes chronic myelomonocytic leukemia.

12 in leukemic cells of a patient with chronic myelomonocytic leukemia.

13 ents with acute myeloid leukemia and chronic myelomonocytic leukemia.

14 ice had a disease similar to the human acute myelomonocytic leukemia.

15 ents with acute myeloid leukemia and chronic myelomonocytic leukemia.

16 r (PDGFbetaR) gene in a patient with chronic myelomonocytic leukemia.

17 5;12) translocation in patients with chronic myelomonocytic leukemia.

18 tosis, including but not limited to, chronic myelomonocytic leukemia.

19 No patient with JXG developed chronic myelomonocytic leukemia.

20 ren with CBL syndrome and transient juvenile myelomonocytic leukemia.

21 elevant proportion of children with juvenile myelomonocytic leukemia.

22 yelodysplastic syndromes (MDSs), and chronic myelomonocytic leukemia.

23 d SRSF2 in 371 children with MDS or juvenile myelomonocytic leukemia.

24 A 3-year-old boy was treated for juvenile myelomonocytic leukemia.

25 econdary acute myeloid leukemia, and chronic myelomonocytic leukemia.

26 , genomic instability, and aggressive, fatal myelomonocytic leukemia.

27 s, myeloproliferative neoplasms, and chronic myelomonocytic leukemia.

28 bling the myeloproliferative form of chronic myelomonocytic leukemia.

29 true NK-cell tumors (n = 18), de novo acute myelomonocytic leukemias (1 of 14, 7%), or mature T-cell

30 ents suffering from MDS (n = 52) and chronic myelomonocytic leukemia-1 (n = 2).

31 ferative neoplasm (SM-MPN), 36 (29%) chronic myelomonocytic leukemia, 28 (23%) myelodysplastic syndro

32 ease: hematologic (MDS 84%, AML 14%, chronic myelomonocytic leukemia 8%), infectious (severe viral 70

33 clinical and molecular features with chronic myelomonocytic leukemia, a similar disease in adults.

34 liferative neoplasm (MPN), including chronic myelomonocytic leukemia, according to the International

35 Juvenile myelomonocytic leukemia, acute myeloid leukemia (AML), a

36 ner gene in the t(8;16) that occurs in acute myelomonocytic leukemia (AML-M4) de novo and rarely in t

37 n specific human cancers, including juvenile myelomonocytic leukemia, an aggressive myeloproliferativ

38 and SRSF2 mutations are frequent in chronic myelomonocytic leukemia and advanced forms of MDS.

39 tions are rare in pediatric MDS and juvenile myelomonocytic leukemia and are unlikely to operate as d

40 e-1 (FIP1L1)-PDGFRalpha, which cause chronic myelomonocytic leukemia and hypereosinophilic syndrome,

41 tantly, Bcl11a is expressed in human chronic myelomonocytic leukemia and juvenile myelomonocytic leuk

42 closely related neoplasms (including chronic myelomonocytic leukemia and MDS-myeloproliferative neopl

43 Exposure of WEHI-3B D+ myelomonocytic leukemia and myeloid LGM-1 cells overexpr

44 tic AML, 7 (13%) of 52 patients with chronic myelomonocytic leukemia, and 1 (1%) of 68 patients with

45 h myelodysplastic syndrome, 118 with chronic myelomonocytic leukemia, and 126 with acute myeloid leuk

46 roblasts, TET2/SRSF2 comutation with chronic myelomonocytic leukemia, and activating CSF3R mutation w

47 All subtypes of myelodysplasia, chronic myelomonocytic leukemia, and acute myeloid leukemia with

48 re common in acute myeloid leukemia, chronic myelomonocytic leukemia, and myelodysplastic syndrome.

49 r gene is frequently inactivated in juvenile myelomonocytic leukemia, and Nf1 mutant mice model this

50 ximately 75% incidence) and SRSF2 in chronic myelomonocytic leukemia ( approximately 28% incidence).

51 ted with marked thrombocytosis, and juvenile myelomonocytic leukemia, are clonal hematologic diseases

52 ptor (TEL-PDGFbetaR) is expressed in chronic myelomonocytic leukemias associated with t(5;12)(q33;p13

53 tive neoplasms (MDS/MPNs), including chronic myelomonocytic leukemia, atypical chronic myeloid leukem

54 We found missense mutations in 2 juvenile myelomonocytic leukemia cases and in 1 child with system

55 uting to the pathogenesis of NS and juvenile myelomonocytic leukemia caused by PTPN11 gain-of-functio

56 MLL-AF6 leukemias as well as in ML2, a human myelomonocytic leukemia cell line bearing the t(6;11)(q2

57 cDNA encoding a CD34 homologue from a canine myelomonocytic leukemia cell line, ML2.

58 rminants of differentiation and apoptosis in myelomonocytic leukemia cells (U937) exposed to the nove

59 lcytosine (ara-C)-induced apoptosis in human myelomonocytic leukemia cells (U937).

60 rrows containing up to 50% lysis-susceptible myelomonocytic leukemia cells (U937).

61 at 50% of the cellular topo I in HL-60 human myelomonocytic leukemia cells became covalently bound to

62 Simultaneous exposure (24 h) of U937 myelomonocytic leukemia cells to 100 nM flavopiridol and

63 2 cells and apoptosis-proficient HL-60 acute myelomonocytic leukemia cells to etoposide were compared

64 n of TF mRNA and protein in SMC and in THP-1 myelomonocytic leukemia cells.

65 sented the spectrum of therapy-induced acute myelomonocytic leukemia/chronic myelomonocytic leukemia/

66 ed patients with higher-risk MDS and chronic myelomonocytic leukemia (CMML) 1:1:1 to azacitidine (75

67 Chronic myelomonocytic leukemia (CMML) and juvenile myelomonocyt

68 s of myeloid malignancies resembling chronic myelomonocytic leukemia (CMML) and myelodysplastic syndr

69 B fusion oncogene is associated with chronic myelomonocytic leukemia (CMML) and results in the expres

70 ations in 5% and 9% of patients with chronic myelomonocytic leukemia (CMML) and sAML, and also in CML

71 Myelodysplastic syndromes and chronic myelomonocytic leukemia (CMML) are characterized by muta

72 myeloid leukemias (sAML) and 15% of chronic myelomonocytic leukemia (CMML) cases.

73 However, monocytoid precursors in chronic myelomonocytic leukemia (CMML) expressed VEGF in an inte

74 3;p13) translocation associated with chronic myelomonocytic leukemia (CMML) generates a TEL/PDGFbetaR

75 Exome sequencing studies in chronic myelomonocytic leukemia (CMML) illustrate a mutational l

76 mouse model resemble those of human chronic myelomonocytic leukemia (CMML) in its transformation to

77 Chronic myelomonocytic leukemia (CMML) is a clonal hematopoietic

78 Chronic myelomonocytic leukemia (CMML) is a hematologic malignan

79 Chronic myelomonocytic leukemia (CMML) is a myelodysplastic synd

80 Chronic myelomonocytic leukemia (CMML) is a myelodysplastic/myel

81 The natural course of chronic myelomonocytic leukemia (CMML) is highly variable but a

82 tients and from 12 of 20 (60%) adult chronic myelomonocytic leukemia (CMML) patients to 10(-9) mol/L

83 Here, we showed that chronic myelomonocytic leukemia (CMML) patients with ASXL1 mutat

84 myeloid leukemia (AML) patients, 32 chronic myelomonocytic leukemia (CMML) patients, and 96 healthy

85 us pathogenesis to those observed in chronic myelomonocytic leukemia (CMML) patients.

86 Human ASXL1 is mutated frequently in chronic myelomonocytic leukemia (CMML) so an ASXL/BAP1 complex m

87 Adults with advanced MDS or chronic myelomonocytic leukemia (CMML) were randomized to 1 of 3

88 r (PDGFbetaR) gene in a patient with chronic myelomonocytic leukemia (CMML) with a t(5;7)(q33;q11.2)

89 omic DNA from 245 patients--119 with chronic myelomonocytic leukemia (CMML), 101 with MDS, 11 with hy

90 oring systems have been proposed for chronic myelomonocytic leukemia (CMML), a disease in which some

91 Chronic myelomonocytic leukemia (CMML), a myelodysplastic/myelop

92 myeloproliferative neoplasms (MPNs), chronic myelomonocytic leukemia (CMML), and acute myeloid leukem

93 te myeloid leukemia (AML), CML, CLL, chronic myelomonocytic leukemia (CMML), and MDS.

94 (CLL), acute myeloid leukemia (AML), chronic myelomonocytic leukemia (CMML), colorectal cancer, endom

95 e myelomonocytic leukemia (JMML) and chronic myelomonocytic leukemia (CMML), including identical soma

96 tion, with a fully penetrant, lethal chronic myelomonocytic leukemia (CMML), which was serially trans

97 ras G12D/+ bone marrow cells develop chronic myelomonocytic leukemia (CMML), while approximately 8% o

98 ng the myeloproliferative variant of chronic myelomonocytic leukemia (CMML), with a prolonged latency

99 NRAS rapidly and efficiently induced chronic myelomonocytic leukemia (CMML)- or acute myeloid leukemi

100 clonal malignancy closely resembling chronic myelomonocytic leukemia (CMML).

101 cogenes in a subset of patients with chronic myelomonocytic leukemia (CMML).

102 been reported in some patients with chronic myelomonocytic leukemia (CMML).

103 ous leukemia (RAEB-T/AML), and 2 had chronic myelomonocytic leukemia (CMML).

104 (5;12) translocation associated with chronic myelomonocytic leukemia (CMML).

105 h myelodysplastic syndrome (MDS) and chronic myelomonocytic leukemia (CMML).

106 T2-WT) and mutant (TET2-MT) cases of chronic myelomonocytic leukemia (CMML).

107 y shown in the related human disease chronic myelomonocytic leukemia (CMML).

108 myelodysplastic syndromes (MDS) and chronic myelomonocytic leukemia (CMML).

109 MPN that accurately models JMML and chronic myelomonocytic leukemia (CMML).

110 n of SRSF2 (Pro95) in 275 cases with chronic myelomonocytic leukemia (CMML).

111 iferative neoplasm, similar to human chronic myelomonocytic leukemia (CMML).

112 ent in acute myeloid leukemia (AML), chronic myelomonocytic leukemia (CMML)/atypical chronic myelogen

113 yeloid malignancies, particularly in chronic myelomonocytic leukemia (CMML; 48%) and MDS/MPD-unclassi

114 uch as chronic myelogenous (CML) and chronic myelomonocytic leukemias (CMML) are frequently induced b

115 derived colonies in 28 patients with chronic myelomonocytic leukemias (CMML), the most frequent MPN/M

116 astic syndrome (MDS) most similar to chronic myelomonocytic leukemia (CMMoL) and one other had dysery

117 with excess blasts (RAEB), and 1 had chronic myelomonocytic leukemia (CMMoL).

118 ergistic terminal differentiation of WEHI-3B myelomonocytic leukemia (D(+)) cells.

119 detection of shared origin of LCH and acute myelomonocytic leukemia driven by TET2-mutant CD34(+) ce

120 ectively analyzed 110 patients with juvenile myelomonocytic leukemia, given single-unit, unrelated do

121 Juvenile myelomonocytic leukemia is an aggressive and frequently

122 Juvenile myelomonocytic leukemia is an aggressive myeloproliferat

123 Chronic myelomonocytic leukemia, isolated 5q- syndrome, unclassi

124 venile chronic myelogenous leukemia/juvenile myelomonocytic leukemia (JCML/JMML).

125 y members are frequently mutated in juvenile myelomonocytic leukemia (JMML) and acute myeloid leukemi

126 features that overlap with those of juvenile myelomonocytic leukemia (JMML) and chronic myelomonocyti

127 acute lymphoblastic leukemia (ALL), juvenile myelomonocytic leukemia (JMML) and LEOPARD syndrome freq

128 hildren with NF1 are predisposed to juvenile myelomonocytic leukemia (JMML) and lethally irradiated m

129 matopoietic malignancies, including juvenile myelomonocytic leukemia (JMML) and T-cell lymphoblastic

130 ctive RAS signaling is prevalent in juvenile myelomonocytic leukemia (JMML) and the myeloproliferativ

131 myelomonocytic leukemia (CMML) and juvenile myelomonocytic leukemia (JMML) are myelodysplastic syndr

132 ) hypersensitivity is a hallmark of juvenile myelomonocytic leukemia (JMML) but has not been systemat

133 ndividuals with Noonan syndrome and juvenile myelomonocytic leukemia (JMML) have germline mutations i

134 Juvenile myelomonocytic leukemia (JMML) is a disease that occurs

135 Juvenile myelomonocytic leukemia (JMML) is a lethal disease of yo

136 Juvenile myelomonocytic leukemia (JMML) is a myeloproliferative d

137 Juvenile myelomonocytic leukemia (JMML) is a pediatric myelodyspl

138 Juvenile myelomonocytic leukemia (JMML) is a pediatric myeloproli

139 Juvenile myelomonocytic leukemia (JMML) is a rare and aggressive

140 Juvenile myelomonocytic leukemia (JMML) is a rare clonal myelopro

141 Juvenile myelomonocytic leukemia (JMML) is a rare pediatric myelo

142 Juvenile myelomonocytic leukemia (JMML) is a typically aggressive

143 Juvenile myelomonocytic leukemia (JMML) is a unique, aggressive h

144 Juvenile myelomonocytic leukemia (JMML) is an aggressive myelopro

145 Juvenile myelomonocytic leukemia (JMML) is an aggressive myelopro

146 Juvenile myelomonocytic leukemia (JMML) is an aggressive myelopro

147 Juvenile myelomonocytic leukemia (JMML) is an aggressive pediatri

148 Juvenile myelomonocytic leukemia (JMML) is an early childhood dis

149 Juvenile myelomonocytic leukemia (JMML) is characterized by hyper

150 Juvenile myelomonocytic leukemia (JMML) is characterized by myelo

151 lear cells from five of seven (71%) juvenile myelomonocytic leukemia (JMML) patients and from 12 of 2

152 myelodysplastic syndrome (MDS) and juvenile myelomonocytic leukemia (JMML) treated in a uniform fash

153 ting the molecular underpinnings of juvenile myelomonocytic leukemia (JMML) with the generation of in

154 own to underlie the pathogenesis of juvenile myelomonocytic leukemia (JMML), a fatal childhood diseas

155 s individuals to the development of juvenile myelomonocytic leukemia (JMML), a fatal myeloproliferati

156 PTPN11 (SHP-2) are associated with juvenile myelomonocytic leukemia (JMML), a myeloproliferative dis

157 sis type 1 (NF1) are predisposed to juvenile myelomonocytic leukemia (JMML), an aggressive myeloproli

158 dysplastic syndrome (A-MDS), 60 had juvenile myelomonocytic leukemia (JMML), and 6 infants with Down

159 al investigate the pathogenesis of juvenile myelomonocytic leukemia (JMML), demonstrating that mutan

160 te promyelocytic leukemia (APL) and juvenile myelomonocytic leukemia (JMML), we evaluated UAB8 isomer

161 ood acute leukemias, in addition to juvenile myelomonocytic leukemia (JMML), which is a myeloprolifer

162 associated with an elevated risk of juvenile myelomonocytic leukemia (JMML).

163 patients with de novo, nonsyndromic juvenile myelomonocytic leukemia (JMML).

164 of hematologic disorders, including juvenile myelomonocytic leukemia (JMML).

165 (ras), is frequently inactivated in juvenile myelomonocytic leukemia (JMML).

166 hildren with NF1 are predisposed to juvenile myelomonocytic leukemia (JMML).

167 myeloid malignancies, particularly juvenile myelomonocytic leukemia (JMML).

168 ferative disorders (MPD), including juvenile myelomonocytic leukemia (JMML).

169 L, and also in CML blast crisis and juvenile myelomonocytic leukemia (JMML).

170 nd the myeloproliferative variant of chronic myelomonocytic leukemia (JMML/MP-CMML).

171 g and is inactivated in a subset of juvenile myelomonocytic leukemias (JMMLs).

172 nd the myeloproliferative variant of chronic myelomonocytic leukemia (MP-CMML) in humans, and both ar

173 ons occur in children with sporadic juvenile myelomonocytic leukemia, myelodysplasic syndrome, B-cell

174 nduced acute myelomonocytic leukemia/chronic myelomonocytic leukemia/myelodysplastic/myeloproliferati

175 th chronic myeloid leukemia (n = 6), chronic myelomonocytic leukemia (n = 6), acute myeloid leukemia

176 antation model efficiently induces a chronic myelomonocytic leukemia- or acute myeloid leukemia-like

177 In 1 juvenile myelomonocytic leukemia patient, the SRSF2 mutation that

178 BCOR is also mutated in chronic myelomonocytic leukemia patients (7.4%) and BCORL1 in AM

179 n 161 of 1458 patients (11%); 26% of chronic myelomonocytic leukemia patients harbored 7q uniparental

180 s and for treatment of the subset of chronic myelomonocytic leukemia patients with a TEL-PDGFR fusion

181 Juvenile myelomonocytic leukemia patients without PTPN11 mutation

182 Decitabine's mechanism of action in chronic myelomonocytic leukemia remains incompletely understood.

183 acute myeloid leukemia) or acquired (chronic myelomonocytic leukemia) RUNX1 mutations.

184 chronic myelomonocytic leukemia and juvenile myelomonocytic leukemia samples.

185 s SM-MPN, systemic mastocytosis with chronic myelomonocytic leukemia, SM-MDS, and systemic mastocytos

186 ures and outcomes of therapy-related chronic myelomonocytic leukemia (t-CMML) and compare with those

187 lomonocytic origin, and a diagnosis of acute myelomonocytic leukemia was rendered.

188 Patients with chronic myelomonocytic leukemia were first screened for JAK2 and

189 actory acute myelogenous leukemia or chronic myelomonocytic leukemia were treated with 10.36 to 37.0

190 ed in human leukemias, particularly juvenile myelomonocytic leukemia, which is characterized by hyper

191 mia [RA]/RA with ringed sideroblasts/chronic myelomonocytic leukemia with < 5% bone marrow blasts, 63

192 ronic myeloproliferative syndrome or chronic myelomonocytic leukemia with eosinophilia.